Publication

Capmatinib in patients with high-level MET-amplified advanced non-small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study.

Wolf, J., Overbeck, T. R., Han, J-Y., Hochmair, M., de Marinis, F., Ohashi, K., Smit, E. F., Power, D., Garon, E. B., Groen, H. J. M., Tan, D. S-W., Waldron-Lynch, M., Le Mouhaer, S., Nwana, N., Giovannini, M. & Heist, R. S., 20-May-2020, In : Journal of Clinical Oncology. 38, 15, 2 p.

Research output: Contribution to journalMeeting AbstractAcademic

APA

Wolf, J., Overbeck, T. R., Han, J-Y., Hochmair, M., de Marinis, F., Ohashi, K., Smit, E. F., Power, D., Garon, E. B., Groen, H. J. M., Tan, D. S-W., Waldron-Lynch, M., Le Mouhaer, S., Nwana, N., Giovannini, M., & Heist, R. S. (2020). Capmatinib in patients with high-level MET-amplified advanced non-small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study. Journal of Clinical Oncology, 38(15).

Author

Wolf, Juergen ; Overbeck, Tobias R. ; Han, Ji-Youn ; Hochmair, Maximilian ; de Marinis, Filippo ; Ohashi, Kadoaki ; Smit, Egbert F. ; Power, Danielle ; Garon, Edward B. ; Groen, Harry J. M. ; Tan, Daniel Shao-Weng ; Waldron-Lynch, Maeve ; Le Mouhaer, Sylvie ; Nwana, Ngozi ; Giovannini, Monica ; Heist, Rebecca Suk. / Capmatinib in patients with high-level MET-amplified advanced non-small cell lung cancer (NSCLC) : results from the phase 2 GEOMETRY mono-1 study. In: Journal of Clinical Oncology. 2020 ; Vol. 38, No. 15.

Harvard

Wolf, J, Overbeck, TR, Han, J-Y, Hochmair, M, de Marinis, F, Ohashi, K, Smit, EF, Power, D, Garon, EB, Groen, HJM, Tan, DS-W, Waldron-Lynch, M, Le Mouhaer, S, Nwana, N, Giovannini, M & Heist, RS 2020, 'Capmatinib in patients with high-level MET-amplified advanced non-small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study.', Journal of Clinical Oncology, vol. 38, no. 15.

Standard

Capmatinib in patients with high-level MET-amplified advanced non-small cell lung cancer (NSCLC) : results from the phase 2 GEOMETRY mono-1 study. / Wolf, Juergen; Overbeck, Tobias R.; Han, Ji-Youn; Hochmair, Maximilian; de Marinis, Filippo; Ohashi, Kadoaki; Smit, Egbert F.; Power, Danielle; Garon, Edward B.; Groen, Harry J. M.; Tan, Daniel Shao-Weng; Waldron-Lynch, Maeve; Le Mouhaer, Sylvie; Nwana, Ngozi; Giovannini, Monica; Heist, Rebecca Suk.

In: Journal of Clinical Oncology, Vol. 38, No. 15, 20.05.2020.

Research output: Contribution to journalMeeting AbstractAcademic

Vancouver

Wolf J, Overbeck TR, Han J-Y, Hochmair M, de Marinis F, Ohashi K et al. Capmatinib in patients with high-level MET-amplified advanced non-small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study. Journal of Clinical Oncology. 2020 May 20;38(15).


BibTeX

@article{1f56a11c03fd487daa5d4d6d11e3aa68,
title = "Capmatinib in patients with high-level MET-amplified advanced non-small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study.",
author = "Juergen Wolf and Overbeck, {Tobias R.} and Ji-Youn Han and Maximilian Hochmair and {de Marinis}, Filippo and Kadoaki Ohashi and Smit, {Egbert F.} and Danielle Power and Garon, {Edward B.} and Groen, {Harry J. M.} and Tan, {Daniel Shao-Weng} and Maeve Waldron-Lynch and {Le Mouhaer}, Sylvie and Ngozi Nwana and Monica Giovannini and Heist, {Rebecca Suk}",
year = "2020",
month = may,
day = "20",
language = "English",
volume = "38",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "AMER SOC CLINICAL ONCOLOGY",
number = "15",

}

RIS

TY - JOUR

T1 - Capmatinib in patients with high-level MET-amplified advanced non-small cell lung cancer (NSCLC)

T2 - results from the phase 2 GEOMETRY mono-1 study.

AU - Wolf, Juergen

AU - Overbeck, Tobias R.

AU - Han, Ji-Youn

AU - Hochmair, Maximilian

AU - de Marinis, Filippo

AU - Ohashi, Kadoaki

AU - Smit, Egbert F.

AU - Power, Danielle

AU - Garon, Edward B.

AU - Groen, Harry J. M.

AU - Tan, Daniel Shao-Weng

AU - Waldron-Lynch, Maeve

AU - Le Mouhaer, Sylvie

AU - Nwana, Ngozi

AU - Giovannini, Monica

AU - Heist, Rebecca Suk

PY - 2020/5/20

Y1 - 2020/5/20

M3 - Meeting Abstract

VL - 38

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 15

ER -

ID: 136156329